Shane Schaffer
Chairman and CEO, Cingulate Inc. (biotech industry)
Shane Schaffer is the Co-founder, Chairman, and Chief Executive Officer of Cingulate Therapeutics, a biopharmaceutical company in Kansas City, Kansas. The company, which is in the Phase 3 clinical stage, specializes in developing next-generation pharmaceutical products, focusing primarily on Attention Deficit/Hyperactivity Disorder (ADHD) and extending into anxiety disorders and insomnia.
Industry Leadership
With a 25-year tenure in pharmaceuticals, he is an expert in drug development and commercialization. His leadership is marked by an entrepreneurial spirit and strategic vision, effectively overseeing product launches, brand planning, joint ventures, life cycle management, and market development, positioning him as a notable figure in biopharmaceuticals and marketing.
Educational Background
He completed his Doctor of Pharmacy at the University of Kansas in 1999, followed by a post-doctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. His fellowship included significant contributions at Pfizer Worldwide Marketing and Morris Plains, enhancing his expertise in the field.
Pfizer Worldwide Marketing, New York, NY
At Pfizer, he assumed the role of Marketing Manager, developing pre-launch strategies and initiating the Global Communications Intranet to facilitate communication between medical and marketing teams. He also aided in creating and implementing the Pfizer Medical and Academic Partnership in Pain Management.
Morris Plains, New Jersey
He was appointed Project Manager and External Research Manager in Morris Plains, overseeing advanced sales training and management development. He also managed Phase IV Medical Research for all marketed brands within the Parke-Davis Medical and Scientific Affairs division.
Professional Career
Throughout his career, Shane Schaffer held several managerial roles at Pfizer, Novartis, and Sanofi, contributing to developing and commercializing several billion-dollar brands.
Novartis Pharmaceuticals Corporation
His passion for the pharmaceutical sector led him to Novartis as a Product Manager for the Ritalin® LA / Focalin™ segments, where he played a pivotal role in enhancing the company's ADHD franchise.
Ritalin® LA & Focaline
He launched Ritalin® LA and Focaline, achieving 166% and 114% budget attainment, respectively, with strategies that resulted in 90% product awareness within three months. His success in multiple product launches earned him the Novartis Business Excellence Award.
ADHD Franchise
In 2004, he led all operations of the ADHD franchise, initiating a faculty development program that trained over 1,400 speakers in three months, earning him the PREMIER Award from the Neuroscience Sales Organization and multiple Novartis Ovation "Above and Beyond" Awards.
Sanofi-Aventis
After Novartis, he significantly impacted Sanofi Aventis, especially during the merger and joint venture phases, demonstrating dynamic professional acumen.
Entrepreneurial Ventures
After Sanofi-Aventis, he joined M|C Communications in Boston as a Consultant, leading the development of business opportunities for primary pharmaceutical targets. In 2009, he founded Sabre Scientific Solutions, LLC, providing consulting services to pharmaceutical and biotechnology companies.
Cingulate Therapeutics LLC
Driven by a passion for improving treatments for ADHD and anxiety disorders, he established Cingulate Therapeutics LLC in January 2013. As CEO, he innovates drug delivery technologies to enhance patient care.
Partnership with Indegene
Cingulate has partnered with Indegene to market its phase-3 oral ADHD medication, CTx-1301, enhancing development and marketing efforts.
Future Outlook
Cingulate is preparing to submit a new drug application for CTX-1301 by mid-2025, aiming for FDA approval.
Philanthropic Engagement
Beyond his professional responsibilities, Shane Schaffer is actively involved with Folds of Honor Charity, which provides educational scholarships to children affected by the loss or disability of military personnel. This demonstrates his commitment to community service.
Industry Leadership
With a 25-year tenure in pharmaceuticals, he is an expert in drug development and commercialization. His leadership is marked by an entrepreneurial spirit and strategic vision, effectively overseeing product launches, brand planning, joint ventures, life cycle management, and market development, positioning him as a notable figure in biopharmaceuticals and marketing.
Educational Background
He completed his Doctor of Pharmacy at the University of Kansas in 1999, followed by a post-doctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. His fellowship included significant contributions at Pfizer Worldwide Marketing and Morris Plains, enhancing his expertise in the field.
Pfizer Worldwide Marketing, New York, NY
At Pfizer, he assumed the role of Marketing Manager, developing pre-launch strategies and initiating the Global Communications Intranet to facilitate communication between medical and marketing teams. He also aided in creating and implementing the Pfizer Medical and Academic Partnership in Pain Management.
Morris Plains, New Jersey
He was appointed Project Manager and External Research Manager in Morris Plains, overseeing advanced sales training and management development. He also managed Phase IV Medical Research for all marketed brands within the Parke-Davis Medical and Scientific Affairs division.
Professional Career
Throughout his career, Shane Schaffer held several managerial roles at Pfizer, Novartis, and Sanofi, contributing to developing and commercializing several billion-dollar brands.
Novartis Pharmaceuticals Corporation
His passion for the pharmaceutical sector led him to Novartis as a Product Manager for the Ritalin® LA / Focalin™ segments, where he played a pivotal role in enhancing the company's ADHD franchise.
Ritalin® LA & Focaline
He launched Ritalin® LA and Focaline, achieving 166% and 114% budget attainment, respectively, with strategies that resulted in 90% product awareness within three months. His success in multiple product launches earned him the Novartis Business Excellence Award.
ADHD Franchise
In 2004, he led all operations of the ADHD franchise, initiating a faculty development program that trained over 1,400 speakers in three months, earning him the PREMIER Award from the Neuroscience Sales Organization and multiple Novartis Ovation "Above and Beyond" Awards.
Sanofi-Aventis
After Novartis, he significantly impacted Sanofi Aventis, especially during the merger and joint venture phases, demonstrating dynamic professional acumen.
Entrepreneurial Ventures
After Sanofi-Aventis, he joined M|C Communications in Boston as a Consultant, leading the development of business opportunities for primary pharmaceutical targets. In 2009, he founded Sabre Scientific Solutions, LLC, providing consulting services to pharmaceutical and biotechnology companies.
Cingulate Therapeutics LLC
Driven by a passion for improving treatments for ADHD and anxiety disorders, he established Cingulate Therapeutics LLC in January 2013. As CEO, he innovates drug delivery technologies to enhance patient care.
Partnership with Indegene
Cingulate has partnered with Indegene to market its phase-3 oral ADHD medication, CTx-1301, enhancing development and marketing efforts.
Future Outlook
Cingulate is preparing to submit a new drug application for CTX-1301 by mid-2025, aiming for FDA approval.
Philanthropic Engagement
Beyond his professional responsibilities, Shane Schaffer is actively involved with Folds of Honor Charity, which provides educational scholarships to children affected by the loss or disability of military personnel. This demonstrates his commitment to community service.
